Developing a Test for the Detection of Ovarian Cancer
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04794322 |
|
Recruitment Status :
Recruiting
First Posted : March 12, 2021
Last Update Posted : May 3, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
The study aims to develop a test for early detection of ovarian cancer using DNA from a growth involving the ovary found in a washing of the uterus (womb), and proteins found in the blood. The samples of the wash and the blood will be taken before surgery. After surgery, doctors will determine whether the participant had ovarian cancer or a benign disease of the ovaries. The tests of the washings and the blood will be examined to see how much the participants with ovarian cancer can be separated from the participants with a benign ovarian disease by the tests. Small amounts from the washing and the blood samples will be sent to four sites for analysis.
Statistical analyses of these data will compare tumor DNA found in the washing of the uterus with proteins in the blood to detect cases of ovarian cancer. The primary goal is to find tests that are mostly positive for cases of ovarian cancer and mostly negative for patients with benign disease. It is hoped that if the tests work for participants with symptoms of the disease that these tests will also work when testing women who have no symptoms. A new study would be needed to see if the tests worked in this situation. If the tests work, this could lead to increasing the number of cases detected in early stage disease and decreasing the number of cases detected in late stage disease. If this change in late stage is large, it will likely reduce deaths due to ovarian cancer.
| Condition or disease | Intervention/treatment |
|---|---|
| Ovarian Neoplasms Ovarian Epithelial Carcinoma Fallopian Tube Neoplasms High Grade Ovarian Serous Adenocarcinoma Stage I Ovarian Cancer Stage II Ovarian Cancer Stage III Ovarian Cancer AJCC v8 Stage IIIA Ovarian Cancer AJCC v8 Stage IIIA1 Ovarian Cancer AJCC v8 Stage IIIA2 Ovarian Cancer AJCC v8 Stage IIIB Ovarian Cancer AJCC v8 Stage IIIC Ovarian Cancer AJCC v8 Stage IV Ovarian Cancer AJCC v8 Stage IVA Ovarian Cancer AJCC v8 Stage IVB Ovarian Cancer AJCC v8 | Diagnostic Test: Uterine lavage, or a wash of the womb Diagnostic Test: Blood sample Diagnostic Test: Pap smear |
The study aims to elucidate the relative contributions to detection of ovarian cancer from tumor DNA in uterine lavage (UL) and protein biomarkers from blood using newly available detection and sample collection technologies. In this document, the term "ovarian cancer" includes fallopian tube cancer. In the first cohort, the study will enroll 200 participants. Enrolling participants prior to surgical diagnosis (e.g. laparoscopy or paracentesis) ensures the study will be "Prospective Collection of Samples, Blinded Evaluation" (PRoBE) compliant. The expectation is that ~50 of these participants will have pathologically confirmed ovarian cancer. In a second cohort, 50 participants will be enrolled. Based on published reports, it is expected that ~5 participants will have microscopic or low volume ovarian cancer. In each cohort, the participants with a pathologic invasive epithelial ovarian cancer diagnosis will be defined as Cases and participants without any ovarian cancer, primary peritoneal cancer (PPC), or other cancer identified due to the surgery, will be defined as Controls. Other cancer groups are: (i) PPC, (ii) non-invasive serous tubal intraepithelial carcinoma (STIC) lesions, (iii) non-epithelial ovarian cancers, and (iv) non-ovarian cancers.
Two sites will sequence DNA obtained from uterine lavages to detect tumor-derived DNA (tDNA): one will carry out Duplex Sequencing of TP53 and the second site will carry out Haloplex sequencing of an 18-gene panel. Two other sites will assay serum proteins: the first will use clinical grade assays for CA125 and HE4, and the second will use research grade assays for these two proteins plus four additional protein biomarker candidates. Statistical analyses of these data will evaluate the relative utility of tDNA and plasma proteins to detect Cases (sensitivity) while limiting detection of Controls (specificity) in these two cohorts. Remaining DNA from UL and blood based biospecimens in form of plasma, serum, and buffy coat will be stored at a biorepository at NCI Frederick for future biomarker investigations which include (but are not limited to) other methods of detecting tDNA from UL, tDNA from plasma, exosomal markers, and additional blood-based and UL biomarker candidates.
Primary objectives:
- To collect samples from 200 participants with suspected ovarian cancer (of which ~50 or more are expected to have pathologically confirmed ovarian cancer) and 50 participants undergoing a risk-reducing salpingo-oophorectomy (of which ~5 are expected to have microscopic or low volume ovarian cancer).
- To test the tDNA from uterine lavage samples for tumor-derived TP53 mutations, using Duplex sequencing, and for potential abnormalities in an 18-gene panel, using Haloplex sequencing
- To test the serum proteins with two assays: the first will use clinical grade assays for CA125 and HE4, and the second will use research grade assays for these two proteins plus four additional protein biomarker candidates.
Outline: Participants undergo two blood draws (one required, one optional) up to 31 days before surgery and a uterine lavage at the time of planned surgery. The tDNA and serum proteins are then extracted from the samples and sent for analysis.
| Study Type : | Observational |
| Estimated Enrollment : | 250 participants |
| Observational Model: | Cohort |
| Time Perspective: | Cross-Sectional |
| Official Title: | Ovarian Cancer Detection by Uterine Lavage DNA and Serum Proteins: a Phase 2 Biomarker Study |
| Actual Study Start Date : | April 13, 2020 |
| Estimated Primary Completion Date : | March 2023 |
| Estimated Study Completion Date : | March 2025 |
| Group/Cohort | Intervention/treatment |
|---|---|
|
Pelvic Mass Cohort (cohort #1)
200 participants scheduled for surgery for suspected ovarian cancer due to a pelvic mass but without a confirmed tissue or cytology diagnosis.
|
Diagnostic Test: Uterine lavage, or a wash of the womb
Uterine lavage is performed during surgery using a flexible, 3-way balloon tipped catheter. The catheter is inserted through the cervix, the balloon expanded and the uterine cavity lavaged using 10 cc of sterile saline which is collected, processed and stored for later analysis. Diagnostic Test: Blood sample Participants undergo two blood draws (one required, one optional) up to 31 days before surgery Diagnostic Test: Pap smear Participants undergo a standard Papanicolaou smear to collect cells and fluid from the cervix. |
|
BRCA1/2 Carriers Cohort (cohort #2)
50 participants with an inherited BRCA1 or BRCA2 deleterious mutation without suspected ovarian cancers who are scheduled for risk-reducing salpingo-oophorectomy (RRSO) to remove ovaries and fallopian tubes.
|
Diagnostic Test: Uterine lavage, or a wash of the womb
Uterine lavage is performed during surgery using a flexible, 3-way balloon tipped catheter. The catheter is inserted through the cervix, the balloon expanded and the uterine cavity lavaged using 10 cc of sterile saline which is collected, processed and stored for later analysis. Diagnostic Test: Blood sample Participants undergo two blood draws (one required, one optional) up to 31 days before surgery Diagnostic Test: Pap smear Participants undergo a standard Papanicolaou smear to collect cells and fluid from the cervix. |
- Genomic biomarkers assessing mutations and methylation of tumor DNA, and protein biomarkers measured as the concentration of a protein in pg/mL, both types of biomarkers measured in the collected biospecimens. [ Time Frame: Through study completion, an average of three years ]Biomarkers that distinguish between ovarian cancer and benign ovarian disease
Biospecimen Retention: Samples With DNA
- Serum (red-top tubes)
- EDTA plasma (purple-top tubes)
- Uterine Lavage supernatant (conical tube)
- Uterine Lavage filter (conical tube)
- Uterine Lavage cell pellet (conical tube)
- Buffy coat (purple-top tubes)
- Tissue sections
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 30 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Has intact uterus (no history of uterine ablation, tubal ligation or bilateral salpingectomy)
- Cohort 1 (n=200 participants): Women scheduled for surgery or diagnostic laparoscopy for suspected but undiagnosed ovarian/fallopian tube cancer
- Cohort 2 (n=50 participants): Known BRCA1 or BRCA2 mutation carrier scheduled for risk-reducing salpingo-oophorectomy
Exclusion Criteria:
- Current tissue or cytology diagnostic procedure positive for ovary cancer or any cancer
- Inability to provide informed consent
- Age less than 30 years
- Inability to obtain the minimum amount of blood
- Inability to obtain the minimum amount of uterine lavage sample
- At risk if blood were drawn (e.g. hemophilia, serious anemia- Hb less than 8.0 gm/dL)
- Prior history of known ovarian or endometrial cancer
- Treatment less than 1 year (excluding hormonal therapy) for cancer that spread beyond its origin
- History of untreated high-grade cervical dysplasia (CIN3)
- History of treated high grade cervical dysplasia (CIN3) with a cytologically abnormal pap smear within the past year. If there is no post treatment Pap smear in the medical record, perform a Pap smear prior to the day of surgery. If this Pap smear is abnormal, the participant is ineligible.
- Currently pregnant
- Known Lynch syndrome
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04794322
| Contact: Jackie Dahlgren | 206 667 3438 | jdahlgre@fredhutch.org |
| United States, Arkansas | |
| University of Arkansas for Medical Sciences | Recruiting |
| Little Rock, Arkansas, United States, 72205 | |
| Contact: Beth Scanlan 501-686-8274 BScanlan@uams.edu | |
| Principal Investigator: Kristin Zorn, MD | |
| United States, California | |
| Kaiser Permanente - San Francisco | Not yet recruiting |
| San Francisco, California, United States, 94115 | |
| Contact: Isabel Perez 415-833-3480 isabel.p.perez@kp.org | |
| Principal Investigator: Christine Garcia, MD | |
| United States, Maryland | |
| Anne Arundel Health System | Recruiting |
| Annapolis, Maryland, United States, 21401 | |
| Contact: Jaci Miller 443-481-5738 jmiller9@aahs.org | |
| Principal Investigator: Monica Jones, MD | |
| Johns Hopkins University School of Medicine | Recruiting |
| Baltimore, Maryland, United States, 21218 | |
| Contact: Rebecca Stone, MD rstone15@jhmi.edu | |
| Principal Investigator: Rebecca Stone, MD | |
| United States, Massachusetts | |
| Massachusetts General Hospital | Not yet recruiting |
| Boston, Massachusetts, United States, 02114 | |
| Contact: Tina Colella 617-643-5150 tcolella@partners.org | |
| Principal Investigator: Amy Bregar, MD | |
| United States, Washington | |
| The Swedish Hospital | Recruiting |
| Seattle, Washington, United States, 98122 | |
| Contact: Robert Pearhill 206-667-3278 rpearhil@fredhutch.org | |
| Principal Investigator: Charles Drescher, MD | |
| Study Director: | Christos Patriotis, PhD | National Cancer Institute (NCI) |
| Responsible Party: | Steven Skates, Principal Investigator, Massachusetts General Hospital |
| ClinicalTrials.gov Identifier: | NCT04794322 |
| Other Study ID Numbers: |
20-450 5U01CA152990 ( U.S. NIH Grant/Contract ) |
| First Posted: | March 12, 2021 Key Record Dates |
| Last Update Posted: | May 3, 2022 |
| Last Verified: | April 2022 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Plan Description: | Individual participant data is not anticipated to be shared. |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | Yes |
|
Uterine Lavage Tumor DNA Serum proteins Ovarian neoplasms Ovarian epithelial carcinoma |
Ovarian cancer Ovarian epithelial cancer Neoplasms Ovarian diseases Early detection |
|
Carcinoma Neoplasms Ovarian Neoplasms Carcinoma, Ovarian Epithelial Cystadenocarcinoma, Serous Fallopian Tube Neoplasms Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Adenocarcinoma Endocrine Gland Neoplasms Neoplasms by Site Ovarian Diseases Adnexal Diseases |
Genital Diseases, Female Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Urogenital Diseases Genital Neoplasms, Female Urogenital Neoplasms Genital Diseases Endocrine System Diseases Gonadal Disorders Cystadenocarcinoma Neoplasms, Cystic, Mucinous, and Serous Fallopian Tube Diseases |